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From numerous studies during the last years it became evident that bacteria and bacterial constituents play a decisive role both
in the maintenance of intestinal immune homeostasis as well as in the development and perpetuation of chronic intestinal
inﬂammation. In this review we focus on the role of bacterial DNA which is a potent immunomodulatory component of the
bacterial ﬂora. Bacterial DNA has been shown to be protective against experimental colitis. In contrast bacterial DNA essentially
contributes totheperpetuation of an already establishedchronic intestinalinﬂammation in aToll-like receptor (TLR)9-dependent
manner. This dichotomic action may be explained by a diﬀerent activation status of essential regulators of TLR signaling like
Glycogen synthase kinase 3-β (GSK3-β) depending on the pre-activation status of the intestinal immune system. In this review
we suggest that regulators of TLR signaling may be interesting therapeutic targets in IBD aiming at the restoration of intestinal
immune homeostasis.
1.Introduction
Chronic intestinal inﬂammation as found in Inﬂammatory
Bowel Diseases (IBD) is common in developed countries
with a prevalence of about 0.5% and, according to the
chronicity and the early onset of disease, has an enormous
socioeconomic impact. Despite great advances in the under-
standing of IBD in the past ten years the aetiology of both
Ulcerative Colitis (UC) and Crohn’s disease (CD) remains
elusive.
The spectrum of possible explanations reaches from the
autoimmune hypothesis which seems to be supported by the
existence of diﬀerent autoantibodies against epithelial cells
in IBD (reviewed in [1]) to the statement that IBD should
be considered as an infectious disease [2]w h i c hm a yd e v e l o p
based on a defective immune response [3, 4].
Although some truth may lay in every speciﬁc hypothesis
the most likely pathophysiologic explanation according to
the current knowledge is that commensal luminal bacteria
w i t hw h i c hw en o r m a l l yl i v ei nf r i e n d l yo re v e ns y m b i o t i c
coexistence are mistakenly recognized as possible pathogens
resulting in a chronic inﬂammatory response.
Obviously, both complex environmental [5] and genetic
factors [6] contribute to the development of IBD. The
most important susceptibility gene described for CD, the
NOD2 gene [7, 8], participates in the innate immune
response to the bacterial wall component muramyl dipep-
tide (MDP). Recently, strong genetic interactions between
polymorphisms in CD-associated variants of NOD2, IL23R,
DLG5, and Toll-like receptor 9 (TLR9, coding for the
intracellular receptor which recognizes bacterial DNA) have
been demonstrated [9]. Taken together, these data argue
for a central role of interactions between bacteria and
the mucosal immune system in the pathogenesis of CD.
Supporting this view, studies from several murine IBD
models underlined the importance of the bacterial ﬂora
in the pathogenesis of chronic intestinal inﬂammation
[10].2 International Journal of Inﬂammation
2. Proinﬂammatory Potential of Bacterial DNA:
CpG-Motif-Containing DNA Contributes to
the Perpetuation of ChronicColitis
During the last years, several groups aimed to characterize
the role of numerous bacterial constituents in murine colitis
models. These studies were put on a new basis by the
identiﬁcation of pattern recognition receptors for microbial
constituentsincludingtheToll-likereceptors(TLRs).Weand
others focused on the role of bacterial DNA as a speciﬁc
bacterial constituent based on its ability to mount a strong
Th1-skewed immune response resulting in extraordinary
high production of tumor necrosis factor (TNF), interferon
(IFN)-γ,orInterleukin(IL)-6[11–14],whichisalsofoundin
experimental and human IBD. Ten years ago, unmethylated
cytosine-guanosine (CpG) sequences were identiﬁed as the
immunostimulatory component of microbial DNA [15],
and ﬁve years later, TLR9 was identiﬁed as the receptor
responsible for CpG recognition [16].
In a ﬁrst approach, we could demonstrate in diﬀer-
ent models of murine colitis that treatment with CpG-
containing oligodeoxynucleotides (CpG-ODN) results in an
exacerbation of established intestinal inﬂammation [17].
Vice versa, TLR9-deﬁcient mice which do not respond to
CpG motifs showed a more than 50% reduced chronic
intestinal inﬂammation two months after the induction of
chronic dextran sodium sulphate- (DSS-) induced colitis.
The latter ﬁnding further indicates an important contribu-
tion of commensal-derived CpG motifs to the perpetuation
of chronic intestinal inﬂammation. This was further con-
ﬁrmed by a strong therapeutic eﬀect of adenoviral-derived
inhibitory motifs in diﬀerent colitis models, including
chronic DSS-induced colitis, the T cell-dependent SCID
transfer model of colitis, and IL-10-deﬁcient mice, which
develop spontaneous colitis [18]. Together these results sup-
port the hypothesis that bacterial constituents and speciﬁ-
callybacterialDNAessentiallycontributetotheperpetuation
of established chronic intestinal inﬂammation [17].
3.Anti-InﬂammatoryPotentialof
BacterialDNA: ProtectiveQualities of
BacterialDNA inIntestinalInﬂammation
andPossible Mechanisms
In sharp contrast to the results arguing for a proinﬂamma-
tory role of bacterial DNA in established intestinal inﬂam-
mation, we and others found that CpG-ODN exposition
had strong protective eﬀects in diﬀerent models of intestinal
inﬂammation when used in a prophylactic approach. Pre-
treatment with CpG-ODN resulted in a strong protection
f r o ma c u t eD S Sc o l i t i sa sw e l la sf r o ma c u t eO x a z o l o n e -a n d
TNBS-induced colitis [19–21]. At ﬁrst sight these surprising
anti-inﬂammatory eﬀects of a potent immune stimulating,
proinﬂammatory bacterial compound seem to be confusing.
One important contribution to these protective eﬀects
seems to be made by intestinal epithelial cells.
Anti-inﬂammatory eﬀects of bacterial DNA on intestinal
epithelial cells with an inhibition of TNF, and IL-8 secretion
as well as NFκB activation were demonstrated in several
reports [22, 23]. It was further shown that the anti-
inﬂammatory eﬀects of bacterial DNA/TLR9 interaction on
intestinal epithelial cells depend on the origin of the bacterial
DNA. In contrast to DNA from pathogenic bacterial strains,
DNA isolated from Lactobacillus rhamnosus GG and other
probiotic bacteria attenuated TNF-induced NFκBa c t i v a t i o n
and NFκB-mediated IL-8 expression [22–24]. Interestingly,
in contrast to the apical stimulation of epithelial cells,
basolateral stimulation resulted in a strong NFκBa c t i v a -
tion and a proinﬂammatory response [25]. The protective,
anti-inﬂammatory response of epithelial cells upon apical
stimulation by DNA derived from commensal or probiotic
strains seems reasonable as this is exactly what occurs under
physiologic conditions in our intestinal tract. Therefore,
apical stimulation of intestinal epithelial cells by bacterial
DNA may essentially contribute to the control of intestinal
homeostasis.
There, however, seems to be no suﬃcient explanation
for the strong protective qualities of TLR9 activation in
colitismodelsasnotonlyorallyadministeredCpG-ODNbut
also systemic CpG-ODN application protects from intestinal
inﬂammation. Another important epithelial cell-dependent
mechanism might be the CpG/TLR9-induced secretion of
bactericidal proteins [26] and/or induction of prostaglandin
E2 [19, 27]b o t ho fw h i c ha r ec o n s i d e r e da sp r o t e c t i v ef o r
the intestinal mucosa. In this case, the activation of epithelial
cells may even occur from the basal membrane after systemic
administration of CpG motifs.
Apart from these possible epithelial cell-mediated mech-
anisms we could identify a CpG/TLR9-mediated modulation
of T-cell function in the CD4+ T-cell-dependent SCID
transfer model of colitis in which colitis is induced in SCID
recipients by adoptively transferred CD4+CD62L+ cells.
Pretreatment of donor mice with CpG-ODN completely
abolished colitis development in SCID recipients. Even more
important, CD4+CD62L+ cells from donors which were
exposed to CpG motifs had the capacity to inhibit the devel-
opment of colitis when cotransferred with colitis-inducing
CD4+CD62L+ cells from untreated donors, indicating a
regulatory potential of CD4+CD62L+ cells from CpG-ODN
treated donors [28]. In fact CD4+ T-cells from germ-free
CpG-ODN-treated donor mice displayed increased PD-1
and FoxP3 expression as potential markers of regulatory T-
cells [29].
Vice versa, transfer of cells from TLR9-deﬁcient mice
resulted in a much more severe intestinal inﬂammation
compared to cells from wildtype controls [28]. This does
not only conﬁrm that CpG motifs can attenuate proin-
ﬂammatory lymphocyte function but also underlines that
the physiological TLR9/CpG interactions are necessary for
immune homeostatic mechanisms such as controlling the
proinﬂammatory potential among CD4+ T cells.
Concerning the further characterization of CD4+-
dependent prophylactic eﬀects of bacterial DNA we asked
three main questions.
(1) Is there a direct TLR9/CpG-interaction on CD4+ T-
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cells or Bcells known to be constitutively TLR9-
positive?
(2) In the case of indirect eﬀects; which cellular and/or
molecular mediators play a role in the modulation of
T-cell functions?
(3) Is TLR9 activation alone suﬃcient to induce prophy-
lactic eﬀects or is it dependent on the coexistence of
other bacterial products (as they are endogenously
found in all colonized mice)?
Our recent results indicated that dendritic cells (DC) are
essential for the mediation of prophylactic TLR9-dependent
eﬀects on T-cells. When DC-depleted donor mice were
treated with CpG-ODN, the colitis-attenuating properties of
transferred T-cells were absent in SCID hosts. In addition,
CpG-ODN preincubation of puriﬁed CD4+ T-cells with
dendritic cells but not with B cells or alone resulted in
an eﬀective reduction of their colitogenic potential after
transfer in SCID hosts [30]. Important molecular mediators
conferring protective CpG eﬀects of bacterial DNA to T cells
seem to be type-I interferons. When type-I interferons were
neutralized in CpG-ODN-treated donor mice, transferred
T-cells again induced severe colitis in SCID hosts. Vice
versa IFN-β treatment of donor mice strongly reduced the
colitogenic potential of transferred CD4+ T-cells. In addition
to these T-cell dependent protective eﬀects of CpG-ODN
inducedtype-Iinterferons,IFN-βhasbeenshowntomediate
colitis-protective eﬀects in a model in which inﬂammation is
only dependent on innate immune responses [31].
The detailed mechanisms by which T-cells modulated
by CpG motifs prevent colitis are still unclear. According to
recent results it seems likely that increased secretion of IL-10
participates in protection from colitis after transfer of CD4+
T cells from CpG-ODN-treated donors [29].
4. BacterialDNA inColitis: Good, Bad, orBoth?
Despite increasing insight in intestinal immune-modulating
properties of TLR9 activation, it is still unclear which
mechanisms explain the dichotomic eﬀect in intestinal
inﬂammation, including both protective and proinﬂam-
matory qualities. According to our results we favour the
hypothesis that the preactivation status of the intestinal
immune system essentially contributes to the outcome of
TLR9 activation, being protective under healthy physiologic
conditions but contributing to a further exacerbation in
already established chronic colonic inﬂammation. A recent
publication underlines that the outcome of TLR9-activation
fundamentally diﬀers depending on the anatomical loca-
tion in the gastrointestinal tract. Hall et al. described a
proinﬂammatory role of DC activated by TLR9 engagement
even under healthy conditions. Such activated DC inhibited
regulatory T-cells and activated Th1 and Th17 T-cells [32].
These proinﬂammatory eﬀects, however, were restricted to
the small intestine in which the number of resident bacteria
stronglydiﬀersfromthatinthecolonalteringthephysiologic
microbial/immunesysteminteractionand,thus,thestatusof
immune activation.
It is important to note that these paradoxical eﬀects
are not restricted to TLR9-activation but have also been
described for other TLR ligands and the bacterial ﬂora in
general.
Itiswelldocumentedthatcommensalshavethepotential
to trigger and perpetuate intestinal inﬂammation in various
spontaneous colitis models like IL-10 deﬁcient mice [33]
which do not develop colitis when kept under germ-
free conditions. This seems to be in contrast to recent
results which indicate that the physiologic colonization
of the gut with commensals is a necessary prerequisite
for a properly working (mucosal) immune system [34–
36]. In fact, the permanent interaction of commensals and
their constituents with the mucosal immune system has
been shown to exert strong protective functions concerning
intestinal inﬂammation. Genetically engineered mice which
are unable to respond to TLR4 or TLR2 ligands such as
LPS or lipoteichoic acid developed a strikingly more severe
intestinal inﬂammation after chemically induced colitis [37].
This has been explained by a reduced barrier function due to
alackofbacteria-inducedmucosalsecretionofdefensinsand
mucins by paneth cells and intestinal epithelial cells. Beyond
this impaired production of protective mucosal molecules,
we could demonstrate—in line with the results in TLR9-
deﬁcient mice described above—that commensals/immune
system interactions also contributed to a less aggressive
behaviour of transferred na¨ ıve CD4+ T-cells in the SCID
transfer model of colitis. Transfer of na¨ ıve CD4+ T-cells
from germ-free donor mice to SPF-housed SCID recipients
resulted in a much more severe intestinal inﬂammation than
transfer of such cells from conventionally housed donors
with a normal bacterial ﬂora [29, 38].
The key helping to resolve these paradoxical eﬀects may
be a diﬀerential regulation of TLR signalling as shown in
Figure 1. Recently, several molecules were identiﬁed which
decide—depending on their state of activation—whether
TLR-activation results in a strong proinﬂammatory response
or a more tolerizing response [39]. For example, activated
glycogen synthase kinase 3-β (GSK3-β)l e dt oas t r o n g
TLR-dependent TNF-, IL-6-, and IL-12-production in DC
whereas TLR-activation in DC with low levels of activated
GSK3-β resulted in a predominant IL-10 production and
production of only low levels of proinﬂammatory cytokines
[40]. We could demonstrate that inhibition of GSK3-β
amelioratedchronicintestinalinﬂammationinchronicDSS-
induced colitis and even abrogated the proinﬂammatory
eﬀects of an additional CpG-ODN exposition seen in
established chronic colitis [41]. Interestingly, human lamina
propriacellsdisplayedanincreasedproductionofproinﬂam-
matory cytokines upon TLR9-activation compared to non-
IBD patients which could be abolished by blockade of GSK3-
β [41]. This underlines a possible relevance for this TLR-
regulating molecule also in the human situation.
Targeting key modulators of TLR signalling such as
GSK3-β may represent a promising option for future thera-
peutic approaches. While current therapeutic principles just
more or less eﬀectively inhibit proinﬂammatory immune
responses at the cost of an increased risk for serious
infections, the restoration of the physiologic equilibrium4 International Journal of Inﬂammation
Induction of regulatory mechanisms:
protection from intestinal inﬂammation
Healthy organism Modulators of TLR
signalling (e.g.
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Figure 1: Whereas in a healthy organism under steady-state conditions CpG DNA/TLR9 activation favours the induction of regulatory
mechanisms in chronic intestinal inﬂammation CpG/TLR9 interaction contributes to the perpetuation of chronic intestinal inﬂammation.
The identiﬁcation of possible regulators of TLR9 activation (e.g. GSK3-β) which have the potential to decide whether TLR activation results
in a more tolerizing or proinﬂammatory response may help to explain these dichotomic eﬀects. These regulators are interesting targets for
therapeutic approaches.
between eﬀectors and inhibitors may help to reestablish the
friendly coexistence of luminal bacteria and the intestinal
immune system. This should not only result in reduced side
eﬀects but may even have the potential to achieve long-
lasting remission.
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